Prenatal screening for cystic fibrosis: Past, present and future

Carolyn (Sue) Richards, Wayne W. Grody

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Prenatal screening for cystic fibrosis is reviewed. The disease, gene involved, molecular basis of disease, genotype/phenotype correlations and pilot trials are discussed, as well as historical perspectives, background and American College of Medical Genetics/American College of Obstetricians and Gynecologists recommendations. A number of complex challenges to the implementation of cystic fibrosis screening exist, including mutation testing of the cystic fibrosis transmembrane conductance regulator gene (CFTR), as well as laboratory and clinical issues. Current technologies for CFTR testing include reverse dot blots, amplification refractory mutation detection systems, oligonucleotide ligation assays, the Invade® assay and NanoChip® system. Emerging technologies are also considered, as well as quality assurance measures including analytical and clinical validation, reporting, residual risk calculations and prenatal diagnosis. An even greater challenge is clinical implementation, which focuses upon education and communication, choosing models, reporting, counseling and prenatal diagnosis.

Original languageEnglish (US)
Pages (from-to)49-62
Number of pages14
JournalExpert Review of Molecular Diagnostics
Volume4
Issue number1
DOIs
StatePublished - Jan 2004

Fingerprint

Prenatal Diagnosis
Cystic Fibrosis
Cystic Fibrosis Transmembrane Conductance Regulator
Regulator Genes
Technology
Mutation
Genetic Association Studies
Oligonucleotides
Ligation
Counseling
Communication
Education
Genes

Keywords

  • ASO
  • ASR
  • CFTR
  • Cystic fibrosis
  • Genetic screening
  • Microarray
  • OLA

ASJC Scopus subject areas

  • Genetics

Cite this

Prenatal screening for cystic fibrosis : Past, present and future. / Richards, Carolyn (Sue); Grody, Wayne W.

In: Expert Review of Molecular Diagnostics, Vol. 4, No. 1, 01.2004, p. 49-62.

Research output: Contribution to journalArticle

@article{74bf543444e24fc6bde9e28c3b71a56c,
title = "Prenatal screening for cystic fibrosis: Past, present and future",
abstract = "Prenatal screening for cystic fibrosis is reviewed. The disease, gene involved, molecular basis of disease, genotype/phenotype correlations and pilot trials are discussed, as well as historical perspectives, background and American College of Medical Genetics/American College of Obstetricians and Gynecologists recommendations. A number of complex challenges to the implementation of cystic fibrosis screening exist, including mutation testing of the cystic fibrosis transmembrane conductance regulator gene (CFTR), as well as laboratory and clinical issues. Current technologies for CFTR testing include reverse dot blots, amplification refractory mutation detection systems, oligonucleotide ligation assays, the Invade{\circledR} assay and NanoChip{\circledR} system. Emerging technologies are also considered, as well as quality assurance measures including analytical and clinical validation, reporting, residual risk calculations and prenatal diagnosis. An even greater challenge is clinical implementation, which focuses upon education and communication, choosing models, reporting, counseling and prenatal diagnosis.",
keywords = "ASO, ASR, CFTR, Cystic fibrosis, Genetic screening, Microarray, OLA",
author = "Richards, {Carolyn (Sue)} and Grody, {Wayne W.}",
year = "2004",
month = "1",
doi = "10.1586/14737159.4.1.49",
language = "English (US)",
volume = "4",
pages = "49--62",
journal = "Expert Review of Molecular Diagnostics",
issn = "1473-7159",
publisher = "Expert Reviews Ltd.",
number = "1",

}

TY - JOUR

T1 - Prenatal screening for cystic fibrosis

T2 - Past, present and future

AU - Richards, Carolyn (Sue)

AU - Grody, Wayne W.

PY - 2004/1

Y1 - 2004/1

N2 - Prenatal screening for cystic fibrosis is reviewed. The disease, gene involved, molecular basis of disease, genotype/phenotype correlations and pilot trials are discussed, as well as historical perspectives, background and American College of Medical Genetics/American College of Obstetricians and Gynecologists recommendations. A number of complex challenges to the implementation of cystic fibrosis screening exist, including mutation testing of the cystic fibrosis transmembrane conductance regulator gene (CFTR), as well as laboratory and clinical issues. Current technologies for CFTR testing include reverse dot blots, amplification refractory mutation detection systems, oligonucleotide ligation assays, the Invade® assay and NanoChip® system. Emerging technologies are also considered, as well as quality assurance measures including analytical and clinical validation, reporting, residual risk calculations and prenatal diagnosis. An even greater challenge is clinical implementation, which focuses upon education and communication, choosing models, reporting, counseling and prenatal diagnosis.

AB - Prenatal screening for cystic fibrosis is reviewed. The disease, gene involved, molecular basis of disease, genotype/phenotype correlations and pilot trials are discussed, as well as historical perspectives, background and American College of Medical Genetics/American College of Obstetricians and Gynecologists recommendations. A number of complex challenges to the implementation of cystic fibrosis screening exist, including mutation testing of the cystic fibrosis transmembrane conductance regulator gene (CFTR), as well as laboratory and clinical issues. Current technologies for CFTR testing include reverse dot blots, amplification refractory mutation detection systems, oligonucleotide ligation assays, the Invade® assay and NanoChip® system. Emerging technologies are also considered, as well as quality assurance measures including analytical and clinical validation, reporting, residual risk calculations and prenatal diagnosis. An even greater challenge is clinical implementation, which focuses upon education and communication, choosing models, reporting, counseling and prenatal diagnosis.

KW - ASO

KW - ASR

KW - CFTR

KW - Cystic fibrosis

KW - Genetic screening

KW - Microarray

KW - OLA

UR - http://www.scopus.com/inward/record.url?scp=0347762807&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0347762807&partnerID=8YFLogxK

U2 - 10.1586/14737159.4.1.49

DO - 10.1586/14737159.4.1.49

M3 - Article

C2 - 14711349

AN - SCOPUS:0347762807

VL - 4

SP - 49

EP - 62

JO - Expert Review of Molecular Diagnostics

JF - Expert Review of Molecular Diagnostics

SN - 1473-7159

IS - 1

ER -